严重肢体威胁性缺血伴静息痛患者早期与延迟血管内干预的成本-效用分析
德国支付方视角的马尔可夫模型,5年时间跨度、7个状态,比较早期裸金属支架(BMS)血管内干预与保守治疗后血管内干预。早期BMS干预5年成本€23,913、增加2.5 QALYs/例;保守后干预成本€18,323、增加2 QALYs/例;增量成本-效用比为€12,438,大截肢减少6%。早期血管内干预具有成本效果,但临床决策应由个体患者资格和医生判断决定。
要点
- 早期BMS干预5年成本€23,913、增加2.5 QALYs/例,保守后干预成本€18,323、增加2 QALYs/例。
- 增量成本-效用比为€12,438,大截肢数量减少6%。
- 结构化、确定性和概率敏感性分析结果稳健。
核心结论
- 早期BMS血管内干预为早期CLTI患者带来更多QALYs并降低大截肢风险。
- 根据世界卫生组织推荐的成本-效果阈值,早期血管内干预非常具有成本效果。
- 然而,早期血管内干预的临床决策应由个体患者资格和医生判断决定。
研究设计与样本
- 马尔可夫模型,5年时间跨度,7个状态:干预、稳定1、大截肢、再干预、稳定2、护理、全因死亡。
- 从德国支付方视角比较BMS血管内干预与保守治疗后血管内干预。
- 转移概率通过汇总多项临床研究结局获得,成本使用德国诊断相关组系统、德国康复基金及相关文献数据估算。
主要发现
- 早期BMS干预5年成本€23,913、增加2.5 QALYs/例;保守后BMS干预5年成本€18,323、增加2 QALYs/例。
- 增量成本-效用比为€12,438。
- 大截肢数量减少6%。
- 结构化、确定性和概率敏感性分析结果稳健。
临床怎么用
- 作者认为早期BMS血管内干预为早期CLTI患者带来更多QALYs并降低大截肢风险,且非常具有成本效果。
- 作者指出早期血管内干预的临床决策应由个体患者资格和医生判断决定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The prevalence of chronic limb-threatening ischemia (CLTI) and poor health outcomes are high in Germany. Serious consequences of CLTI such as amputation and mortality can be effectively prevented by the early use of evidence-based therapeutic measures such as endovascular intervention. We have developed a cost-utility analysis to compare endovascular intervention with bare metal stents (BMSs) and endovascular intervention after conservative treatment from the German payer perspective. METHODS: A Markov model, with a 5-year time horizon and seven states, was developed: (1) intervention, (2) stable 1, (3) major amputation, (4) reintervention, (5) stable 2, (6) care, and (7) all-cause death. Transition probabilities were obtained by pooling the outcomes from multiple clinical studies. The costs were estimated using data from the German diagnosis-related group system, the German rehabilitation fund, and related literature. Health-state utilities were obtained from the reported data. The primary outcomes were the quality-adjusted life-years (QALYs) and costs. RESULTS: Early BMS intervention after 5 years resulted in a cost of €23,913 and an increase of 2.5 QALYs per patient, and endovascular intervention with BMS after conservative treatment after 5 years resulted in a cost of €18,323 and an increase of 2 QALYs per patient. The incremental cost-effectiveness ratio was €12,438. The number of major amputations was reduced by 6%. The results of the structural, deterministic, and probabilistic sensitivity analyses were robust. CONCLUSIONS: Early endovascular intervention with BMS resulted in more QALYs and a reduced risk of major amputation for early-stage CLTI patients. Our results showed that early endovascular intervention is very cost-effective according to World Health Organization recommended cost-effectiveness thresholds. However, the clinical decision regarding the use of early endovascular intervention should be determined by individual patient-level eligibility and the physician's judgment.
引用
- Vadia R, Malyar N, Stargardt T, et al. Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia patients with rest pain. J Vasc Surg. 2022. PMID: 35843509. doi:10.1016/j.jvs.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。